Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Pharmacy-Based Infectious Diseases Management Programs Incorporating CLIA-Waived Point-of-Care Tests.

Herbin SR, Klepser DG, Klepser ME.

J Clin Microbiol. 2020 Feb 19. pii: JCM.00726-19. doi: 10.1128/JCM.00726-19. [Epub ahead of print] Review.

PMID:
32075903
2.

Evaluation of a community pharmacy-based influenza and group A streptococcal pharyngitis disease management program using polymerase chain reaction point-of-care testing.

Klepser DG, Klepser ME, Murry JS, Borden H, Olsen KM.

J Am Pharm Assoc (2003). 2019 Nov - Dec;59(6):872-879. doi: 10.1016/j.japh.2019.07.011. Epub 2019 Aug 29.

PMID:
31474527
3.

Acceptability and feasibility of a pharmacist-led HIV pre-exposure prophylaxis (PrEP) program in the Midwestern United States.

Havens JP, Scarsi KK, Sayles H, Klepser DG, Swindells S, Bares SH.

Open Forum Infect Dis. 2019 Oct 1;6(10). pii: ofz365. doi: 10.1093/ofid/ofz365.

4.

Predictors of Cost and Incidence of 30-Day Readmissions Following Hospitalizations for Schizophrenia and Psychotic Disorders: A Nationwide Analysis.

Wani RJ, Kathe NJ, Klepser DG.

Qual Manag Health Care. 2019 Jul/Sep;28(3):130-138. doi: 10.1097/QMH.0000000000000223.

PMID:
31246775
5.

Predictors and Costs of 30-Day Readmissions After Index Hospitalizations for Alcohol-Related Disorders in U.S. Adults.

Wani RJ, Tak HJ, Watanabe-Galloway S, Klepser DG, Wehbi NK, Chen LW, Wilson FA.

Alcohol Clin Exp Res. 2019 May;43(5):857-868. doi: 10.1111/acer.14021. Epub 2019 Apr 10.

PMID:
30861148
6.

Time and motion study of pharmacist prescribing of oral hormonal contraceptives in Oregon community pharmacies.

Frost TP, Klepser DG, Small DC, Doyle IC.

J Am Pharm Assoc (2003). 2019 Mar - Apr;59(2):222-227. doi: 10.1016/j.japh.2018.12.015. Epub 2019 Feb 8.

PMID:
30745187
7.

Impact of implementing a technology platform in community pharmacies to increase adult immunizations rates.

Wehbi NK, Wani RJ, Klepser DG, Murry J, Khan AS.

Vaccine. 2019 Jan 3;37(1):56-60. doi: 10.1016/j.vaccine.2018.11.043. Epub 2018 Nov 22.

PMID:
30471954
8.

Midwest pharmacists' familiarity, experience, and willingness to provide pre-exposure prophylaxis (PrEP) for HIV.

Broekhuis JM, Scarsi KK, Sayles HR, Klepser DG, Havens JP, Swindells S, Bares SH.

PLoS One. 2018 Nov 14;13(11):e0207372. doi: 10.1371/journal.pone.0207372. eCollection 2018.

9.

Development of a standardized approach for managing opioids in adults with chronic noncancer pain.

Downes JM, Klepser DG, Foster J, Nelson M.

Am J Health Syst Pharm. 2018 Mar 1;75(5):321-326. doi: 10.2146/ajhp161012.

PMID:
29472515
10.

Point-of-care testing in the pharmacy: how is the field evolving?

Klepser DG, Klepser ME.

Expert Rev Mol Diagn. 2018 Jan;18(1):5-6. doi: 10.1080/14737159.2018.1392240. Epub 2017 Oct 19. No abstract available.

PMID:
29034791
11.

Observation of a Pharmacist-Conducted Group A Streptococcal Pharyngitis Point-of-Care Test: A Time and Motion Study.

Corn CE, Klepser DG, Dering-Anderson AM, Brown TG, Klepser ME, Smith JK.

J Pharm Pract. 2018 Jun;31(3):284-291. doi: 10.1177/0897190017710518. Epub 2017 May 28.

PMID:
28553774
12.

Utilization of influenza and streptococcal pharyngitis point-of-care testing in the community pharmacy practice setting.

Klepser DG, Klepser ME, Smith JK, Dering-Anderson AM, Nelson M, Pohren LE.

Res Social Adm Pharm. 2018 Apr;14(4):356-359. doi: 10.1016/j.sapharm.2017.04.012. Epub 2017 May 2.

PMID:
28479019
13.

Collaborative practice agreements a useful tool for researchers.

Klepser DG.

J Am Pharm Assoc (2003). 2016 Nov - Dec;56(6):618-619. doi: 10.1016/j.japh.2016.10.005. No abstract available.

PMID:
27836125
14.

Community pharmacist-physician collaborative streptococcal pharyngitis management program.

Klepser DG, Klepser ME, Dering-Anderson AM, Morse JA, Smith JK, Klepser SA.

J Am Pharm Assoc (2003). 2016 May-Jun;56(3):323-329.e1. doi: 10.1016/j.japh.2015.11.013. Epub 2016 Apr 7.

PMID:
27067554
15.

Effectiveness of a pharmacist-physician collaborative program to manage influenza-like illness.

Klepser ME, Klepser DG, Dering-Anderson AM, Morse JA, Smith JK, Klepser SA.

J Am Pharm Assoc (2003). 2016 Jan;56(1):14-21. doi: 10.1016/j.japh.2015.11.008.

PMID:
26802915
16.

Consumer Opinions of Health Information Exchange, e-Prescribing, and Personal Health Records.

Cochran GL, Lander L, Morien M, Lomelin DE, Brittin J, Reker C, Klepser DG.

Perspect Health Inf Manag. 2015 Nov 1;12:1e. eCollection 2015.

17.

Use of CLIA-waived point-of-care tests for infectious diseases in community pharmacies in the United States.

Weber NC, Klepser ME, Akers JM, Klepser DG, Adams AJ.

Expert Rev Mol Diagn. 2016;16(2):253-64. doi: 10.1586/14737159.2015.1116388. Epub 2015 Nov 27. Review.

PMID:
26560318
18.

Health care provider perceptions of a query-based health information exchange: barriers and benefits.

Cochran GL, Lander L, Morien M, Lomelin DE, Sayles H, Klepser DG.

J Innov Health Inform. 2015 Jun 3;22(2):302-8. doi: 10.14236/jhi.v22i2.135.

19.

Health Care Resource Utilization and Costs for Influenza-like Illness Among Midwestern Health Plan Members.

Klepser DG, Corn CE, Schmidt M, Dering-Anderson AM, Klepser ME.

J Manag Care Spec Pharm. 2015 Jul;21(7):568-73.

20.

Antimicrobial stewardship in outpatient settings: leveraging innovative physician-pharmacist collaborations to reduce antibiotic resistance.

Klepser ME, Adams AJ, Klepser DG.

Health Secur. 2015 May-Jun;13(3):166-73. doi: 10.1089/hs.2014.0083.

PMID:
26042860
21.

Public health perceptions of community pharmacy partnership opportunities.

Roberts GE, Rubin SE, Smith JK, Adams AJ, Klepser DG.

J Public Health Manag Pract. 2015 Jul-Aug;21(4):413-5. doi: 10.1097/PHH.0000000000000276. No abstract available.

PMID:
26010695
22.

Consumer interest in community pharmacy HIV screening services.

Darin KM, Scarsi KK, Klepser DG, Klepser SA, Reeves A, Young M, Klepser ME.

J Am Pharm Assoc (2003). 2015 Jan-Feb;55(1):67-72. doi: 10.1331/JAPhA.2015.14069.

PMID:
25414989
23.

Anti-inflammatory effects of rosuvastatin in healthy subjects: a prospective longitudinal study.

McGuire TR, Kalil AC, Dobesh PP, Klepser DG, Olsen KM.

Curr Pharm Des. 2014;20(7):1156-60.

PMID:
24467235
24.

PCMHs, ACOs, and medication management: lessons learned from early research partnerships.

Schnur ES, Adams AJ, Klepser DG, Doucette WR, Scott DM.

J Manag Care Pharm. 2014 Feb;20(2):201-5.

25.

From physician intent to the pharmacy label: prevalence and description of discrepancies from a cross-sectional evaluation of electronic prescriptions.

Cochran GL, Klepser DG, Morien M, Lomelin D, Schainost R, Lander L.

BMJ Qual Saf. 2014 Mar;23(3):223-30. doi: 10.1136/bmjqs-2013-002089. Epub 2013 Oct 8.

PMID:
24106311
26.

Proton pump inhibitors and acute kidney injury: a nested case-control study.

Klepser DG, Collier DS, Cochran GL.

BMC Nephrol. 2013 Jul 16;14:150. doi: 10.1186/1471-2369-14-150.

27.

Barriers to electronic prescribing: Nebraska pharmacists' perspective.

Lander L, Klepser DG, Cochran GL, Lomelin DE, Morien M.

J Rural Health. 2013 Winter;29(1):119-24. doi: 10.1111/j.1748-0361.2012.00438.x. Epub 2012 Oct 2.

PMID:
23289663
28.

Cost-effectiveness of pharmacist-provided treatment of adult pharyngitis.

Klepser DG, Bisanz SE, Klepser ME.

Am J Manag Care. 2012 Apr 1;18(4):e145-54.

PMID:
22554040
29.

Adherence and dosing frequency of common medications for cardiovascular patients.

Bae JP, Dobesh PP, Klepser DG, Anderson JD, Zagar AJ, McCollam PL, Tomlin ME.

Am J Manag Care. 2012 Mar;18(3):139-46.

PMID:
22435907
30.

Trends in community pharmacy counts and closures before and after the implementation of Medicare part D.

Klepser DG, Xu L, Ullrich F, Mueller KJ.

J Rural Health. 2011 Spring;27(2):168-75. doi: 10.1111/j.1748-0361.2010.00342.x. Epub 2010 Oct 15.

PMID:
21457309
31.

Student-run low-income family medicine clinic: controlling costs while providing comprehensive medication management.

Dvoracek JJ, Cook KM, Klepser DG.

J Am Pharm Assoc (2003). 2010 May-Jun;50(3):384-7. doi: 10.1331/JAPhA.2010.09058.

PMID:
20452913
32.

Reduction in mortality associated with statin therapy in patients with severe sepsis.

Dobesh PP, Klepser DG, McGuire TR, Morgan CW, Olsen KM.

Pharmacotherapy. 2009 Jun;29(6):621-30. doi: 10.1592/phco.29.6.621.

PMID:
19476415
33.

Are patent expirations the answer to improving patient adherence?

Klepser DG.

Am J Manag Care. 2008 Dec;14(12):787-8. No abstract available.

34.

Factors affecting demand among older adults for medication therapy management services.

Brooks JM, Unni EJ, Klepser DG, Urmie JM, Farris KB, Doucette WR.

Res Social Adm Pharm. 2008 Dec;4(4):309-19. doi: 10.1016/j.sapharm.2007.11.003. Epub 2008 Aug 8.

PMID:
19064238
35.

Pharmacoeconomic analysis of microbiologic techniques for differentiating staphylococci directly from blood culture bottles.

Hermsen ED, Shull SS, Klepser DG, Iwen PC, Armbrust A, Garrett J, Freifeld AG, Rupp ME.

J Clin Microbiol. 2008 Sep;46(9):2924-9. doi: 10.1128/JCM.00623-08. Epub 2008 Jul 9.

36.

Retail pharmacy market structure and performance.

Brooks JM, Doucette WR, Wan S, Klepser DG.

Inquiry. 2008 Spring;45(1):75-88. Review.

PMID:
18524293
37.

Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance.

Klepser DG, Huether JR, Handke LJ, Williams CE.

J Manag Care Pharm. 2007 Nov-Dec;13(9):765-77.

38.

The effect of physician and health plan market concentration on prices in commercial health insurance markets.

Schneider JE, Li P, Klepser DG, Peterson NA, Brown TT, Scheffler RM.

Int J Health Care Finance Econ. 2008 Mar;8(1):13-26.

PMID:
18038246
39.

Effect of local competition on the willingness of community pharmacies to supply medication therapy management services.

Brooks JM, Klepser DG, Urmie JM, Farris KB, Doucette WR.

J Health Hum Serv Adm. 2007 Summer;30(1):4-27.

PMID:
17557694
40.

Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin's lymphoma cases during first-course chemotherapy.

Chrischilles EA, Klepser DG, Brooks JM, Voelker MD, Chen-Hardee SS, Scott SD, Link BK, Delgado DJ.

Pharmacotherapy. 2005 May;25(5):668-75.

PMID:
15899728
41.

An evaluation of managing and educating patients on the risk of glucocorticoid-induced osteoporosis.

McDonough RP, Doucette WR, Kumbera P, Klepser DG.

Value Health. 2005 Jan-Feb;8(1):24-31.

42.

Population-based medication reviews: a descriptive analysis of the medication issues identified in a medicare not-for-profit prescription discount program.

Farris KB, Ganther-Urmie JM, Fang G, Doucette WR, Brooks JM, Klepser DG, Fries DJ, Kuhle CL.

Ann Pharmacother. 2004 Nov;38(11):1823-9. Epub 2004 Oct 12.

PMID:
15479770
43.

Health care resource utilization associated with treatment of penicillin-susceptible and -nonsusceptible isolates of Streptococcus pneumoniae.

Klepser ME, Klepser DG, Ernst EJ, Brooks J, Diekema DJ, Mozaffari E, Hendrickson J, Doern GV.

Pharmacotherapy. 2003 Mar;23(3):349-59.

PMID:
12627934
44.

The dynamics of health care resource utilization.

Klepser ME, Klepser DG.

Pharmacotherapy. 2002 Feb;22(2 Pt 2):39S-44S.

PMID:
11837546
45.

Pitfalls associated with commonly used methods for pharmacoeconomic analyses.

Klepser DG.

Pharmacotherapy. 2002 Feb;22(2 Pt 2):35S-38S.

PMID:
11837545

Supplemental Content

Loading ...
Support Center